Pathology Committee

The EpSSG Pathology committee leads on the histological classification of sarcomas with systematic review of all sarcomas enrolled on the different clinical studies and trials. The aims of histological review are to improve the diagnostic reproducibility across the participating countries (especially for rare entities) and to provide standardised reports that capture key data (morphologic, molecular and immunohistochemical).

In the current FAR-RMS trial, the pathology committee has a critical role in creating a repository of virtual slides of all rhabdomyosarcomas enrolled in the trial. This is of fundamental importance for the histological-molecular correlation, and for identifying novel clinically significant subtypes. Members of the pathology committee similarly have an integral role in the MyKids study and the molecular profiling of non-rhabdomyosarcoma soft tissue tumours.

The Pathology Committee closely collaborates with the Biology Committee in order to identify potential morphologic/immunohistochemical surrogates of molecular alterations important for future therapeutic strategies.